MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Concomitant Medication Use and Levodopa Equivalent Daily Dose Requirements After Foslevodopa/foscarbidopa Initiation

D. Santos Garcia, L. Bergmann, B. Bergmans, F. Bergquist, S. Criswell, V. Fung, J. Jia, P. Kukreja, N. Pavasia, W. Robieson, Z. Zhang, D. Standaert (A Coruña, Spain)

Meeting: 2022 International Congress

Abstract Number: 763

Keywords: Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: To evaluate patterns of concomitant medication use and levodopa equivalent daily dose (LEDD) during a 52 week study with foslevodopa/foscarbidopa (LDP/CDP).

Background: LDP/CDP is a soluble formulation of levodopa/carbidopa prodrugs delivered as continuous subcutaneous infusion (CSCI) 24-hour daily. LDP/CDP provides individually adjustable doses to control motor complications in patients with advanced PD (aPD).

Method: Study M15-741 (NCT03781167) is a 52-week, phase 3, open-label, single-arm, multicenter, global (US, EU, Australia, and Japan) study to assess the local and systemic safety, tolerability, and efficacy of 24-hour daily CSCI of LDP/CDP. The LDP/CDP dose was individualized to achieve an optimal clinical response for each patient. Intake of prior and allowable concomitant medication classes (adamantane derivatives, tropine derivatives, catechol-O-methyltransferase [COMT] inhibitors, monoamine oxidase-B [MAO-B] inhibitors, tertiary amines, other anti-Parkinson drugs, and non-ergolinic dopamine agonists) were summarized by study visit. LEDD for LDP/CDP was evaluated at each study visit.

Results: The analysis included 244 patients with aPD. At baseline (BL), the proportion of patients taking 0, 1, 2, and ≥ 3 classes of PD medications were 0%, 13.5%, 28.3%, and 58.2%, respectively. At week 52, there was a reduction in the number of patients taking ≥ 3 PD medications (10.3%) that was associated with a shift in the number of patients taking 0, (LDP/CDP monotherapy; 23.0%), 1 (43.7%) and 2 (23.0%) classes of PD medications (Figure). The LEDD of LDP/CDP (CSCI and extra doses) remained fairly stable over time (range, 1621.9–1847.0 mg/day).

Conclusion: As demonstrated by the treatment patterns observed, there was flexibility in the LDP/CDP dose and use of concomitant medications. For patients with aPD who initiated LDP/CDP treatment, 23% achieved monotherapy with LDP/CDP by week 52. The daily dose of LDP/CDP remained stable over time while the use of concomitant medications decreased, indicating a reduced need for co-medications to adequately control motor fluctuation in patients with aPD.

Figure 1

To cite this abstract in AMA style:

D. Santos Garcia, L. Bergmann, B. Bergmans, F. Bergquist, S. Criswell, V. Fung, J. Jia, P. Kukreja, N. Pavasia, W. Robieson, Z. Zhang, D. Standaert. Concomitant Medication Use and Levodopa Equivalent Daily Dose Requirements After Foslevodopa/foscarbidopa Initiation [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/concomitant-medication-use-and-levodopa-equivalent-daily-dose-requirements-after-foslevodopa-foscarbidopa-initiation/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/concomitant-medication-use-and-levodopa-equivalent-daily-dose-requirements-after-foslevodopa-foscarbidopa-initiation/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley